The 1166 A/C polymorphism of the angiotensin II type 1 receptor gene does not correlate with the blood pressure response to angiotensin II in patients with CHF

S. L. Malendowicz, Ulrich P. Jorde, P. V. Ennezat, T. Chen, L. Murray, E. H. Sonnenblick, T. Evans, T. H. LeJemtel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Whether the 1166 (A/C) polymorphism of the Angiotensin II (AII) type 1 receptor (AT1R) gene does correlate with increased vascular reactivity to AII is unclear. Accordingly we measured the blood pressure response to exogenous AII and determined the 1166A/C AT1R gene polymorphism in patients with Chronic Heart Failure (CHF). 40 patients with CHF and functional capacity compatible with NYHA class II-III were studied. All patients were genotyped for the 1166 A/C polymorphism. The frequency of the C allele was 0.2. Radial Artery Systolic Pressure (RASP) was non-invasively monitored using a Colins Pilot Monitor 9200. Ascending doses of AII were administered intravenously to increase RASP by 20 mmHg (AII Pd 20). Patients with CHF exhibited a 10-fold variability in their response to AII with Pd 20 ranging from 2.5 to 25 ng/kg. Patients with AA or AC/CC genotype, had similar AII Pd 20: 11.35 ± 1.18 vs. 13.21 ± 2.2 respectively (p = 0.42). Similarly, among the patients with decreased vascular reactivity who required ≥ 10 ng/kg of AII to achieve Pd 20 (n = 29), RASP response to 10 ng/kg of AII was comparable among patients with AA and AC/CC genotype 22.5 ± 2.8 vs. 21.9 ± 3.3 mmHg respectively (p = 0.9). In patients with CHF, the doses of AII required to increase BP by 20 mmHg demonstrate a 10-fold variability. The 1166A/C polymorphism of the AT1R gene does not account for the wide range of AII Pd 20. Factors other than 1166A/C polymorphism of the AT1R gene are likely to determine BP response to exogenous AII in CHF patients.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalJournal of Clinical and Basic Cardiology
Volume4
Issue number1
StatePublished - 2001

Fingerprint

Angiotensin Type 1 Receptor
Angiotensin II
Heart Failure
Blood Pressure
Genes
Radial Artery
Blood Vessels
Genotype
Gene Frequency

Keywords

  • Angiotensin receptor
  • Blood pressure
  • Gene
  • Polymorphism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The 1166 A/C polymorphism of the angiotensin II type 1 receptor gene does not correlate with the blood pressure response to angiotensin II in patients with CHF. / Malendowicz, S. L.; Jorde, Ulrich P.; Ennezat, P. V.; Chen, T.; Murray, L.; Sonnenblick, E. H.; Evans, T.; LeJemtel, T. H.

In: Journal of Clinical and Basic Cardiology, Vol. 4, No. 1, 2001, p. 75-77.

Research output: Contribution to journalArticle

Malendowicz, S. L. ; Jorde, Ulrich P. ; Ennezat, P. V. ; Chen, T. ; Murray, L. ; Sonnenblick, E. H. ; Evans, T. ; LeJemtel, T. H. / The 1166 A/C polymorphism of the angiotensin II type 1 receptor gene does not correlate with the blood pressure response to angiotensin II in patients with CHF. In: Journal of Clinical and Basic Cardiology. 2001 ; Vol. 4, No. 1. pp. 75-77.
@article{9ff0109e49514848b3719f66275b4339,
title = "The 1166 A/C polymorphism of the angiotensin II type 1 receptor gene does not correlate with the blood pressure response to angiotensin II in patients with CHF",
abstract = "Whether the 1166 (A/C) polymorphism of the Angiotensin II (AII) type 1 receptor (AT1R) gene does correlate with increased vascular reactivity to AII is unclear. Accordingly we measured the blood pressure response to exogenous AII and determined the 1166A/C AT1R gene polymorphism in patients with Chronic Heart Failure (CHF). 40 patients with CHF and functional capacity compatible with NYHA class II-III were studied. All patients were genotyped for the 1166 A/C polymorphism. The frequency of the C allele was 0.2. Radial Artery Systolic Pressure (RASP) was non-invasively monitored using a Colins Pilot Monitor 9200. Ascending doses of AII were administered intravenously to increase RASP by 20 mmHg (AII Pd 20). Patients with CHF exhibited a 10-fold variability in their response to AII with Pd 20 ranging from 2.5 to 25 ng/kg. Patients with AA or AC/CC genotype, had similar AII Pd 20: 11.35 ± 1.18 vs. 13.21 ± 2.2 respectively (p = 0.42). Similarly, among the patients with decreased vascular reactivity who required ≥ 10 ng/kg of AII to achieve Pd 20 (n = 29), RASP response to 10 ng/kg of AII was comparable among patients with AA and AC/CC genotype 22.5 ± 2.8 vs. 21.9 ± 3.3 mmHg respectively (p = 0.9). In patients with CHF, the doses of AII required to increase BP by 20 mmHg demonstrate a 10-fold variability. The 1166A/C polymorphism of the AT1R gene does not account for the wide range of AII Pd 20. Factors other than 1166A/C polymorphism of the AT1R gene are likely to determine BP response to exogenous AII in CHF patients.",
keywords = "Angiotensin receptor, Blood pressure, Gene, Polymorphism",
author = "Malendowicz, {S. L.} and Jorde, {Ulrich P.} and Ennezat, {P. V.} and T. Chen and L. Murray and Sonnenblick, {E. H.} and T. Evans and LeJemtel, {T. H.}",
year = "2001",
language = "English (US)",
volume = "4",
pages = "75--77",
journal = "Journal of Clinical and Basic Cardiology",
issn = "1561-2775",
publisher = "Krause und Pachernegg GmbH",
number = "1",

}

TY - JOUR

T1 - The 1166 A/C polymorphism of the angiotensin II type 1 receptor gene does not correlate with the blood pressure response to angiotensin II in patients with CHF

AU - Malendowicz, S. L.

AU - Jorde, Ulrich P.

AU - Ennezat, P. V.

AU - Chen, T.

AU - Murray, L.

AU - Sonnenblick, E. H.

AU - Evans, T.

AU - LeJemtel, T. H.

PY - 2001

Y1 - 2001

N2 - Whether the 1166 (A/C) polymorphism of the Angiotensin II (AII) type 1 receptor (AT1R) gene does correlate with increased vascular reactivity to AII is unclear. Accordingly we measured the blood pressure response to exogenous AII and determined the 1166A/C AT1R gene polymorphism in patients with Chronic Heart Failure (CHF). 40 patients with CHF and functional capacity compatible with NYHA class II-III were studied. All patients were genotyped for the 1166 A/C polymorphism. The frequency of the C allele was 0.2. Radial Artery Systolic Pressure (RASP) was non-invasively monitored using a Colins Pilot Monitor 9200. Ascending doses of AII were administered intravenously to increase RASP by 20 mmHg (AII Pd 20). Patients with CHF exhibited a 10-fold variability in their response to AII with Pd 20 ranging from 2.5 to 25 ng/kg. Patients with AA or AC/CC genotype, had similar AII Pd 20: 11.35 ± 1.18 vs. 13.21 ± 2.2 respectively (p = 0.42). Similarly, among the patients with decreased vascular reactivity who required ≥ 10 ng/kg of AII to achieve Pd 20 (n = 29), RASP response to 10 ng/kg of AII was comparable among patients with AA and AC/CC genotype 22.5 ± 2.8 vs. 21.9 ± 3.3 mmHg respectively (p = 0.9). In patients with CHF, the doses of AII required to increase BP by 20 mmHg demonstrate a 10-fold variability. The 1166A/C polymorphism of the AT1R gene does not account for the wide range of AII Pd 20. Factors other than 1166A/C polymorphism of the AT1R gene are likely to determine BP response to exogenous AII in CHF patients.

AB - Whether the 1166 (A/C) polymorphism of the Angiotensin II (AII) type 1 receptor (AT1R) gene does correlate with increased vascular reactivity to AII is unclear. Accordingly we measured the blood pressure response to exogenous AII and determined the 1166A/C AT1R gene polymorphism in patients with Chronic Heart Failure (CHF). 40 patients with CHF and functional capacity compatible with NYHA class II-III were studied. All patients were genotyped for the 1166 A/C polymorphism. The frequency of the C allele was 0.2. Radial Artery Systolic Pressure (RASP) was non-invasively monitored using a Colins Pilot Monitor 9200. Ascending doses of AII were administered intravenously to increase RASP by 20 mmHg (AII Pd 20). Patients with CHF exhibited a 10-fold variability in their response to AII with Pd 20 ranging from 2.5 to 25 ng/kg. Patients with AA or AC/CC genotype, had similar AII Pd 20: 11.35 ± 1.18 vs. 13.21 ± 2.2 respectively (p = 0.42). Similarly, among the patients with decreased vascular reactivity who required ≥ 10 ng/kg of AII to achieve Pd 20 (n = 29), RASP response to 10 ng/kg of AII was comparable among patients with AA and AC/CC genotype 22.5 ± 2.8 vs. 21.9 ± 3.3 mmHg respectively (p = 0.9). In patients with CHF, the doses of AII required to increase BP by 20 mmHg demonstrate a 10-fold variability. The 1166A/C polymorphism of the AT1R gene does not account for the wide range of AII Pd 20. Factors other than 1166A/C polymorphism of the AT1R gene are likely to determine BP response to exogenous AII in CHF patients.

KW - Angiotensin receptor

KW - Blood pressure

KW - Gene

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=0035003615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035003615&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 75

EP - 77

JO - Journal of Clinical and Basic Cardiology

JF - Journal of Clinical and Basic Cardiology

SN - 1561-2775

IS - 1

ER -